Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedearly_phase_1

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

NCT06034197
completedphase_2

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

NCT06145048
completedphase_2

Phase 2 Study of VGT-309 in Lung Cancer

NCT05400226

Clinical Trials (3)

Showing 3 of 3 trials
NCT06034197Early Phase 1

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

Terminated
NCT06145048Phase 2

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Completed
NCT05400226Phase 2

Phase 2 Study of VGT-309 in Lung Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3